Effectiveness and safety of oral prednisolone vs tofacitinib in management of oral and mucocutaneous lichen planus: Investigator blind, active-controlled, randomized clinical trial. - NI

College of Medicine and Sagore Dutta Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年7月25日

研究概览

暂无简介。

•1.All clinically and histologically proven cases of oral lichen planus (OLP) with or without dermatological manifestations
•2.Patients suffering from lichen planus who have not responded to topical therapy and conventional treatment.
•3.Recurring cases of lichen planus
•4.No use of any systemic therapy in patients suffering from lichen planus in the previous 4 weeks prior to enrolment in the study
•5.Patients willing to come for follow up at regular intervals

•1.Extremes of age comprising children below the age of 18years and elderly patients above the age of 65 years will be excluded from the study.
•2.Pregnant and lactating women
•3.Patients with asymptomatic OLP
•3.Patients with uncontrolled diabetes mellitus, hypertension
•4.Patient under immunosuppressive drugs.
•5.Patients with concomitant immune disorders, heart disease, renal failure, malignancy
•6.Patients with neurological or psychiatric disorders.
•7.Patients who have participated in any clinical trial within the last 3 months.

发起方

College of Medicine and Sagore Dutta Hospital